U.S. Department of Health and Human Services
COVID-19 has been associated with inflammation and a prothrombotic state, with increases in fibrin, fibrin degradation products, fibrinogen, and D-dimer levels. In some studies, elevations in these markers have been associated with worse clinical outcomes. This section provides recommendations about antithrombotic therapy in nonhospitalized patients without evidence of venous thromboembolism; hospitalized, nonpregnant adults without evidence of venous thromboembolism; hospitalized children; considerations during lactation and pregnancy; and managing antithrombotic therapy in patients with COVID-19.
- Click on the PDF link below to access this section.
- Return to this page. Click “Next” below access the next section.
- The last section provides a link to the quiz, registration, payment, and certificate.